A

mgen may face yet another setback with its controversial Repatha cholesterol-lowering drug because an influential nonprofit may soon lower its value rating for the medicine.

In a new report, the Institute for Clinical and Economic Review indicated that recently released clinical trial results prompted a reassessment, which will be lower than an initial cost-effective analysis issued two years ago. At the time, ICER pegged the value of the drug at between $5,400 and $7,700, which was notably lower than the $14,000 list price.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy